Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with the chronic lung disease.

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis bronchiectasis, marking the first treatment approved for this indication, according to a press release from Insmed.

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.